RAN-QUINAPRIL TABLET

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Dostępny od:

RANBAXY PHARMACEUTICALS CANADA INC.

Kod ATC:

C09AA06

INN (International Nazwa):

QUINAPRIL

Dawkowanie:

40MG

Forma farmaceutyczna:

TABLET

Skład:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG

Droga podania:

ORAL

Sztuk w opakowaniu:

30/1000

Typ recepty:

Prescription

Dziedzina terapeutyczna:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0123206004; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2014-10-17

Charakterystyka produktu

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................